Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01099540

Enrollment

Registered

2010-04-07

Start date

2010-04-30

Completion date

2013-03-31

Last updated

2015-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumor

Keywords

neuroendocrine tumor

Brief summary

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Interventions

DRUGPazopanib

Pazopanib 800 mg qd daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion criteria

* poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Design outcomes

Primary

Measure	Time frame
response rate	1~2 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026